Pharmaceuticals, Biotechnology and Life Sciences
Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting “FOR” the Company’s Highly Qualified Director Nominees…
Subcutaneous administration generally safe and well-tolerated across multiple doses>80% reduction in anti-VEGF intravitreal injection burden in wet AMD and DME…
600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance…
Optigo wins People’s Choice Award at the recent Eyecelerator meeting in Park City for proprietary drug anchoring, potential to transform…
MESQUITE, NV, May 06, 2025 (GLOBE NEWSWIRE) — March 10, 2025 – Mesquite, NV – Dogecoin Cash, Inc. ($CBDS), a…
Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic…
VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF…
Positive Phase 1 data from lead program, SENTI-202, recently presented at the AACR Annual Meeting: SENTI-202 was generally well tolerated,…
Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2025…
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company…